Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

5 clinical studies listed.

Filters:

Complete Response

Tundra lists 5 Complete Response clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ACTIVE NOT RECRUITING

NCT01844986

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.

Gender: FEMALE

Ages: 18 Years - 130 Years

Updated: 2025-12-10

38 states

Newly Diagnosed
Advanced Ovarian Cancer
FIGO Stage III-IV
+4
ACTIVE NOT RECRUITING

NCT06087718

Feasibility of the Maastro Applicator in Rectal Cancer

The goal of this interventional pilot trial is to confirm that Maastro endoluminal HDR ( High Dose Radiation) contact brachytherapy boosting is feasible and may increase the chance of functional organ sparing of the rectum in patients with rectal cancer. Participants will be treated with chemoradiotherapy and an endoluminal boost with the Maastro applicator.

Gender: All

Ages: 18 Years - Any

Updated: 2025-08-14

1 state

Rectal Cancer
Feasibility
Toxicity
+5
RECRUITING

NCT06811844

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined with camrelizumab in patients with locally advanced nasopharyngeal carcinoma.

Gender: All

Ages: 18 Years - 65 Years

Updated: 2025-07-01

2 states

Nasopharyngeal Neoplasms
PD-1 Inhibitor
Induction Therapy
+2
ACTIVE NOT RECRUITING

NCT03522246

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2025-06-24

64 states

Epithelial Ovarian Cancer
Primary Peritoneal
Fallopian Tube Cancer
+4
NOT YET RECRUITING

NCT06743555

Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study

The SAVED LUNG study is a pilot Phase I trial evaluating safety and feasibility of observation versus standard-of-care surgery in operable Stage II-III (excluding N3) NSCLC patients (PD-L1 ≥50%) who achieve complete clinical response following neoadjuvant platinum-doublet chemotherapy and immunotherapy. Participants are randomized to observation or surgery after rigorous restaging, with primary endpoints focusing on safety and feasibility. Secondary objectives include rates of cross-over to surgery, event-free survival, and overall survival, while exploratory endpoints examine ctDNA clearance and its association with clinical response.

Gender: All

Ages: 18 Years - Any

Updated: 2024-12-20

1 state

Non-Small Cell Lung Cancer
Immunotherapy
Neoadjuvant Therapy
+2